Navigation Links
Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
Date:9/1/2009

About ProLindac(TM): ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion. Access has previously announced that it has licensed ProLindac to Aosaikang Medicinal Group ("ASK") for the Greater China Region and to JCOM, Ltd for South Korea. Under these agreements both of these partners will be conducting Phase 2 combination studies with ProLindac in specific tumor types at their expense based on these results.

About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and T
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NuAire Laboratory Economic Stimulus Package -- Free Accessories or Factory Options
2. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
3. Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights
4. Access Pharmaceuticals CEO Interviewed on Financial Website
5. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
6. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
7. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
8. Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China
9. Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
10. Ochsner and LSUHSC Partner to Provide Better Local Access to Comprehensive Cancer Care
11. Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Today, Americord Registry, one ... announced Andrew Horne , a partner at Kirkland & ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... Americord,s Advisory Board," says Martin Smithmyer , CEO of ... his legal career that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and ... insights on mechanics of fecal microbiota transplantation in C. difficile patients. , SAN ... of patients undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... does not sacrifice selectivity to achieve faster flow rates in comparison to nylon ... with significant open space to allow easy liquid flow while trapping particulates as ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... services to the federal government, announced in a paper published this week in ... a potential problem with the diagnostic techniques currently used to detect the Ebola ...
Breaking Biology Technology:Americord Registry Announces Andrew Horne as Advisory Board Member 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3New Nanofiber Membrane Provides Fast, Efficient Filtration 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4
... University of Wisconsin-Madison spinoff developing a drug for people with ... $1.6 million, of which it has received the first portion, ... developing drug candidates. , ,Trevor Twose, Mithridion's CEO, said the ... that he may hire six people by the end of ...
... was sent an announcement of pending Illinois broadband legislation ... Here's its synopsis: , Creates the Universal Access to ... Services (CMS) to create and maintain a map of ... publicly held broadband infrastructure shall be available for lease ...
... to a biotech company (it is priority #1, #2, and ... sense) companies are continually faced with the challenge of raising ... article will focus on venture capital financing results for 2005. ... from Burrill and Company's data. Burrill's perspective is more towards ...
Cached Biology Technology:Mithridion raises $1.6M through angel networks 2Proposed Illinois broadband act falls short 2Proposed Illinois broadband act falls short 3Proposed Illinois broadband act falls short 4Proposed Illinois broadband act falls short 5U.S. VC funding flat in 2005 while life science funding grows 2U.S. VC funding flat in 2005 while life science funding grows 3U.S. VC funding flat in 2005 while life science funding grows 4
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... This news release is available in German ... fever, diarrhoea -- these symptoms could point to an infection ... is based on a syringe-like injection apparatus called injectisome. For ... at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, ...
... oligodendrocyte precursor cells (OPC) migrate to the lesion and ... the Institute of Molecular Cell Biology at Johannes Gutenberg ... protein regulates the direction and movement of OPC toward ... at the surface of OPCs and down-regulated as they ...
... Western Reserve University has granted a two-year technology ... a hand-held device that diagnoses malaria more quickly, ... Diagnostic Group LLC, the startup formed last summer ... of Engineering, also raised $250,000 to "field-test" the ...
Cached Biology News:3-D molecular syringes 23-D molecular syringes 3Scientists at Mainz University decode mechanisms of cell orientation in the brain 2CWRU grants Disease Diagnostic Group option on malaria diagnostic device 2